Could a tropical berry boost immunotherapy for kidney cancer?
NCT ID NCT06049576
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the combination. The study looks at changes in gut bacteria and tumor response, aiming to see if the prebiotic helps the immune system fight cancer better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camu camu (a prebiotic fruit extract) combined with nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to
If it works, adding camu camu could boost the immune system's ability to fight kidney cancer, potentially improving how well standard immunotherapy works.
What could go wrong
This is a very early phase 1 trial with only 31 people, so it is mainly checking safety and dosing. It is too soon to know if camu camu truly helps, and it may not lead to better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States